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A B S T R A C T
Becker Muscular dystrophy (BMD) is an X-linked syndrome characterized by progressive muscle weakness. BMD is generally less severe than Duchenne Muscular
Dystrophy. BMD is caused by mutations in the dystrophin gene that normally give rise to the production of a truncated but partially functional dystrophin protein. We
generated an induced pluripotent cell line from dermal fibroblasts of a BMD patient carrying a splice mutation in the dystrophin gene (c.1705-8 T>C). The iPSC cell-
line displayed the characteristic pluripotent-like morphology, expressed pluripotency markers, differentiated into cells of the three germ layers and had a normal
karyotype.
Resource Table:
Unique stem cell line identifier CCMi004-A
Alternative name(s) of stem cell line BMD3 c.13
Institution Centro Cardiologico Monzino-IRCCS
Contact information of distributor Aoife Gowran; aoife.gowran@ccfm.it
Type of cell line iPSC
Origin Human
Additional origin info Age: 5 (at skin biopsy)
Sex: M
Ethnicity if known: Caucasian
Cell Source Dermal fibroblasts
Clonality Clonal
Method of reprogramming Episomal vectors containing the reprogramming factors: hL-MYC, hLIN28, hSOX2, hKLF4, hOCT4.
Genetic Modification YES
Type of Modification Spontaneous mutation
Associated disease Becker Muscular dystrophy
Gene/locus DMD gene, Xp21.2-p21.1
Method of modification No modification
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date July 2019
Cell line repository/bank The Telethon Biobank and the Eurobiobank
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Resource utility
This cell line provides a tool to investigate novel patho-mechanisms
caused by mutations in the dystrophin gene and will help the screening
of novel therapeutics.
Resource Details
Becker Muscular Dystrophy (BMD) is an X-linked syndrome char-
acterized by progressive skeletal muscle weakness and the development
of cardiomyopathy. BMD is generally less severe than Duchenne
Muscular Dystrophy (DMD) the other forms of muscular dystrophy
(Flanigan, 2014). BMD is caused by mutations in the dystrophin (DMD)
gene, that codes for a structural protein localized under the sarcolemma.
The dystrophin protein links the actin cytoskeleton to the extracellular
matrix via the dystrophin-associated protein complex (DAPC)
(Constantin, 2014). BMD mutations preserve the dystrophin reading
frame allowing the expression of a truncated but partially functional
dystrophin (Muntoni et al., 2003). There is significant phenotypic het-
erogeneity in BMD, from asymptomatic patients to those restricted to a
wheelchair by age sixteen. Although the majority of patients survive to
late adulthood (50–60 years), many develop cardiomyopathy char-
acterized by a progressive decline in ejection fraction and heart failure.
After obtaining informed consent and institutional ethical approval
dermal fibroblasts were isolated from a 5-year-old child with BMD. To
protect privacy, no identifying patient information is included. The
subject presented with incidental HyperCKemia i.e. abnormal levels of
creatine kinase (CK) in the blood. CK is released into the circulation as a
consequence of deteriorating myofibrils, which is caused by the lack of
mechanical stabilization of the sarcolemma normally provided by
functional dystrophin. At time of biopsy the patient was still ambulant.
The patient's fibroblasts were electroporated with plasmids encoding L-
MYC, LIN28, SOX2, KLF4, OCT4 (Okita et al., 2007) and reprogrammed
to induced pluripotent stem cells (iPSCs) under feeder-free conditions.
The iPSC cell-line here described, named CCMi004-A, was char-
acterized for iPSC pluripotent cell morphology (Fig. 1A) and expression
of the pluripotency marker SSEA4 by immunofluorescence (Fig. 1B).
The majority of CCMi004-A cells (81%) were positive for the presence
of SSEA4 as demonstrated by FACS experiments, with no significant
difference compared to well-characterized iPSC cell lines derived from
healthy individuals (Fig. 1C).
In vitro trilineage differentiation assays showed that CCMi004-A is
able to differentiate into cells of each germ layer (Ectoderm NESTIN/
PAX6, mesoderm cardiac troponin T type 2 CTNT2 and endoderm
SOX17; Fig. 1D). Karyotype analyses, performed on more than 30 me-
taphases, demonstrated that the iPSC line has a normal karyotype
(Fig. 1E). Sanger sequencing, performed on genomic DNA extracted
from CCMi004-A showed the presence of the single nucleotide sub-
stitution T>C in the intronic region spanning exons 14 and 15
(c.1705–8 T>C) (Fig. 1F). This mutation alters the splicing of exon 15
allowing the production of a shorter mRNA. Short Tandem Repeat
(STR) analysis of 17 total loci (LGC Standards and ATCC) showed that
CCMi004-A iPSCs were unique (no match to any other cell line in the
ATCC-STR database or DSMZ) and matched the patient's primary fi-
broblasts. Mycoplasma-free CCMi004-A (Supplementary Figure 1) were
harvested and frozen in mFreSR™ (Stemcell Technologies) and trans-
ferred to long-term nitrogen storage.
Materials and methods
Reprogramming of BMD patient's fibroblasts to iPSCs
The fibroblasts were isolated from the patient's skin biopsy by explant
culture. Fibroblasts were transfected with 1.25 µg of episomal vectors
(pCXLE-hUL, pCXLE-hSK, pCXLE-hOCT4; Addgene) by electroporation
(1650 V, 10 s, 3 pulse; Neon™ transfection system, Invitrogen), transferred
into a single well of a 6-well plate coated with human recombinant vi-
tronectin (Life Technologies) and cultured at 37 °C with 5% CO2. On day 3
post transfection transfected fibroblasts were cultured with a reprogram-
ming media (ReproTeSR™, Stemcell Technologies) which was replaced
every day. Colonies were harvested when they reached 1000 μm in dia-
meter by manual isolation using a 25 Gauge sterile syringe and transferred
into an individual well of a 12-well plate containing mTeSR1™ media
(Stemcell Technologies) supplemented with RevitaCell™ (Life
Technologies). iPSCs were maintained in mTeSR1™ media with daily
media changes. Every 3–4 days, iPSCs were non-enzymatically passaged
with ReLeSR™ (Stemcell Technologies) and replated as small aggregates in
mTeSR1™ media containing RevitaCell™. Stock vials of iPSCs were har-
vested in mFreSR™ (Stemcell Technologies) and stored at −180 °C for
future experiments (Table 1).
Pluripotency marker immunocytochemistry
CCMi004-A were cultured in vitronectin-coated chamber slides for
analysis of pluripotency proteins (SSEA4). iPSCs were fixed in 4% for-
maldehyde (10 min RT), treated with 0.1% Triton-X 100 in PBS for
5 min for permeabilization and with 3% BSA in PBS for 1 h for blocking.
Antibodies were diluted in 0.3% BSA in PBS and incubated at 4 °C
overnight (primary) and 1 h at RT (secondary). Nuclei were counter-
stained with Hoechst 33342 (Invitrogen; 1:500 in PBS) for 15 min at
RT. Slides were analysed with a confocal microscope (LSM710, Zeiss).
All antibody details are listed in Table 2.
Flow cytometry
iPSCs detached using ReLeSR™ (Stemcell Technologies), were re-
suspended in PBS/0.5 mM EDTA, fixed for 20 min on ice using BD
Cytofix™ buffer (BD Biosciences) and stained with SSEA4 antibody (1 h,
4 °C) followed by the specific fluorescently tagged secondary antibody
(1 h 4 °C). All the antibodies were diluted in 0.1% BSA, 0.5 mM EDTA in
PBS. iPSCs were analysed using a Gallios (Beckman Coulter) flow cyt-
ometer and Kaluza software (version 2.5, Beckman Coulter). iPSC lines
from healthy donors were used as characterization controls.
In vitro trilineage differentiation potential assay
CCMi004-A cells were differentiated into cells of the ectodermal or
endodermal lineages using the STEMdiff™ trilineage differentiation kit
(Stemcell Technologies) according to the manufacturer's instructions. For
differentiation along the mesodermal lineage, cells were treated with small
molecules targeting the Wnt pathway in order to induce cardiomyocyte
differentiation according to Lian et al. (2013). Differentiated cells were
stained with the specific antibodies and analysed by confocal microscopy
(LSM710, Zeiss). All antibody details are listed in Table 2.
Karyotyping
Metaphase chromosomes were prepared from iPSC cultures at pas-
sage 25 (P25). After 48–96 h, colcemid (10 μg/ml) was added for 3 h at
37 °C. Cells were incubated in hypotonic solution (Sodium Citrate 0.6%,
KCl 0.13%) at RT for 10 min, washed with Ibraimov solution (acetic
acid 5%), fixed with methanol/acetic acid (3:1) in Optichrome (28 °C,
42% rH), Q-banded and photographed. Karyotype images were
Ethical approval The study was approved by the ethical committee of the European Institute of Oncology and Monzino Heart Centre (Istituto Europeo di
Oncologia e dal Centro Cardiologico Monzino, IEO-CCM, CEA20150411, ammed. 20190528 AN/sd). Informed consent was given to
donate biopsy material for use in research to The Telethon Biobank or The Eurobiobank which were accessed via grant numbers GTB12001
and GUP13013 respectively.
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obtained at 100X magnification (Olympus BX microscope, U-CMAD3
Olympus camera). About 30 metaphases were analysed and karyotyped
using an automated cytogenetic imaging system (MetaSystems Gmbh,
Germany).
Dystrophin mutation analyses by Sanger sequencing
DNA was extracted from iPSCs using the QIAamp DNA Mini Kit
(Qiagen) according to manufacturer's instructions. The DMD intron
14–15 was amplified with GoTaq Flexi DNA polymerase (Promega)
using exon flanking primers (95 °C-56 °C-72 °C, 35 cycles). PCR pro-
ducts were then sent to Microsynth for direct Sanger sequencing.
Electropherograms were aligned and analysed with ChromasPro soft-
ware (Technelysium Pty Ltd). DNA extracted from iPSCs obtained from
a healthy individual's dermal fibroblasts were used as controls.
STR analysis
STR analysis was performed by the ATCC cell-line authentication
service. Seventeen STR loci plus the gender-determining locus,
Fig. 1. Characterization of Becker Muscular Dystrophy induced pluripotent stem cell line (CCMi004-A).
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Amelogenin, were amplified using the commercially available
PowerPlex® 18D Kit from Promega. The cell-line sample was processed
using the ABI Prism® 3500xl Genetic Analyzer. Data were analyzed
using GeneMapper® ID-X v1.2 software (Applied Biosystems).
Appropriate positive and negative controls were run and confirmed for
each sample submitted.
Mycoplasma analyses
To verify the absence of Mycoplasma we used EZ-PCR Mycoplasma
Detection Kit (Biological Industries) according to the manufacturer's
instructions. A positive control was included in the kit.
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Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1A
Phenotype Qualitative analysis
Immunocytochemistry
Positive for SSEA4 Fig. 1B
Quantitative analysis: Flow cytometry Positive for SSEA4 (81%) Fig. 1C
Genotype Karyotype (Q-banding) and resolution 46,XY, Resolution 400 band level Fig. 1E
Identity Microsatellite PCR (mPCR) OR Not performed
STR analysis 18 loci test, all matched submitted in archive with journal
Mutation analysis (IF APPLICABLE) Sequencing DMD mutation c.1705-8 T>C Fig. 1F
Southern Blot OR WGS Not performed
Microbiology and virology Mycoplasma Mycoplasma testing by PCR; Negative Supplementary figure 1
Differentiation potential Directed differentiation Positive for: NESTIN/PAX6, ectoderm; CTNT2,
mesoderm;SOX17, endoderm.
Fig. 1D
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C Not performed
Genotype additional info (OPTIONAL) Blood group genotyping Not performed
HLA tissue typing Not performed
Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-citometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-SSEA4 1:200 (1/100 for
FACS)
Abcam Cat# ab16287, RRID:AB_778073;
Differentiation Markers Rabbit anti-SOX17
Mouse anti-CTNT2
Mouse anti-NESTIN
Rabbit anti-PAX6
1:300
1:300
1:150
1:300
Cell Signaling Inc. Cat# 81778, RRID:AB_2650582;&&&Thermo Fisher Scientific Cat# MA-
512960, RRID: AB_11000742;&&&Abcam Cat# ab22035, RRID: AB_446723&&&BioLegend
Cat# PRB-278P, RRID: AB_291612
Secondary antibodies Anti-Mouse IgG, Alexa®Fluor 488
Goat anti-Rabbit IgG (H + L) Highly
Cross-Adsorbed Secondary Antibody,
Alexa®Fluor 594
1:400 (for
SSEA4)
1:300 (for
NESTIN)
1:200(for
CTNT2)
1:300 (for PAX6)
Thermo Fisher Scientific Cat# A11059, RRID:AB_2534106;&&&Thermo Fisher Scientific Cat#
A-11037&&&RRID: AB_2534095
Primers
Target Forward/Reverse primer (5′−3′)
Genotyping DMD intron14-15 c.1705-8 T>C F: CCGCTGGGTTCTTTTACAAG
R: AGCCAGTTGTGTGAATCTTGT
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